Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Preferred Dividend Payments (2021)

Werewolf Therapeutics (HOWL) has disclosed Preferred Dividend Payments for 1 consecutive years, with $56.9 million as the latest value for Q2 2021.

  • Quarterly Preferred Dividend Payments changed N/A to $56.9 million in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $56.9 million through Mar 2022, changed N/A year-over-year, with the annual reading at $151.9 million for FY2021, 1053.08% up from the prior year.
  • Preferred Dividend Payments for Q2 2021 was $56.9 million at Werewolf Therapeutics, down from $95.0 million in the prior quarter.
  • The five-year high for Preferred Dividend Payments was $95.0 million in Q1 2021, with the low at $56.9 million in Q2 2021.